This company is no longer active
SESN Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sesen Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.58 |
| 52 Week High | US$19.30 |
| 52 Week Low | US$7.30 |
| Beta | 0.83 |
| 1 Month Change | 8.32% |
| 3 Month Change | 21.04% |
| 1 Year Change | -7.05% |
| 3 Year Change | -12.67% |
| 5 Year Change | -45.32% |
| Change since IPO | -94.20% |
Recent News & Updates
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Shareholder Returns
| SESN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.5% | -2.6% | 3.9% |
| 1Y | -7.1% | -12.1% | 11.6% |
Return vs Industry: SESN underperformed the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: SESN exceeded the US Market which returned -8.5% over the past year.
Price Volatility
| SESN volatility | |
|---|---|
| SESN Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: SESN has not had significant price volatility in the past 3 months.
Volatility Over Time: SESN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 17 | Thomas Cannell | sesenbio.com |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.
Sesen Bio, Inc. Fundamentals Summary
| SESN fundamental statistics | |
|---|---|
| Market cap | US$2.56b |
| Earnings (TTM) | -US$19.88m |
| Revenue (TTM) | US$40.00m |
64.0x
P/S Ratio-128.7x
P/E RatioIs SESN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SESN income statement (TTM) | |
|---|---|
| Revenue | US$40.00m |
| Cost of Revenue | US$1.99m |
| Gross Profit | US$38.02m |
| Other Expenses | US$57.90m |
| Earnings | -US$19.88m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 95.04% |
| Net Profit Margin | -49.71% |
| Debt/Equity Ratio | 0% |
How did SESN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/08 08:58 |
| End of Day Share Price | 2023/03/07 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sesen Bio, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |